Indian pharmaceutical stocks remain a long-term opportunity despite concerns over US tariffs, according to Srinivas Rao Ravuri, Chief Investment Officer at Bajaj Life Insurance.

Ravuri said he prefers contract development and manufacturing organizations, or CDMOs, over generic drug makers. That distinction matters because CDMOs are more closely tied to outsourced development and manufacturing work for global drug companies, while generic makers are more exposed to pricing pressure and regulatory shifts in core export markets.

He also said that value is beginning to emerge in the information technology sector even as artificial intelligence-related headwinds continue to weigh on the space. For investors, that puts the focus on whether current market concerns are already reflected in valuations rather than on any immediate change in the operating environment.

The chief investment officer’s comments come as investors continue to assess the outlook for pharma and IT stocks amid shifting global trade dynamics, tariff concerns and changing technology spending patterns. Both sectors remain closely watched because they are important parts of India’s equity market and are often used by investors to gauge the impact of external demand trends on domestic companies.

Bajaj Life CIO backs pharma CDMOs, sees value emerging in IT despite AI headwinds